Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
2
100%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution2 total trials
Phase 4Post-market surveillance
2(100.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(1)
Other(1)

Detailed Status

Completed1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 42 (100.0%)

Trials by Status

completed150%
unknown150%

Recent Activity

0 active trials
Showing 2 of 2
completedphase_4

Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes

NCT05065879
unknownphase_4

Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes

NCT05065892

Clinical Trials (2)

Showing 2 of 2 trials
NCT05065879Phase 4

Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes

Completed
NCT05065892Phase 4

Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes

Unknown

All 2 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
2